New eczema injection challenges market leader in major Head-to-Head trial
Disease control
Not yet recruiting
This study aims to see if a new injectable medication called GS101 works as well as the established treatment Dupixent for controlling moderate-to-severe eczema. About 572 adults with long-term eczema will receive either GS101 or Dupixent injections to compare their effectiveness…
Phase: PHASE3 • Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC